In the news release, Aldeyra Therapeutics Announces 2017
Research and Development Day, issued 27-Sep-2017 by Aldeyra Therapeutics, Inc. over PR
Newswire, we are advised by the company that the date in the second
paragraph should read "Tuesday, October 10,
2017" rather than "Monday, October
10, 2017" as originally issued. The complete, corrected
release follows:
Aldeyra Therapeutics Announces 2017 Research and Development Day
LEXINGTON, Mass., Sept. 27, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage
biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to endogenous
aldehyde toxicity today announced that it will host a Research and
Development Day to discuss new clinical results from the Company's
Phase 2 clinical trials in allergic conjunctivitis and dry eye
disease, as well as market opportunities in ocular
inflammation. The agenda will include key opinion
leaders John Sheppard, M.D.,
Professor of Ophthalmology at Eastern Virginia
Medical School and President, Virginia Eye Consultants;
Gary Novack, PhD, President,
PharmaLogic Development, Inc. and Visiting Professor of
Pharmacology and Ophthalmology, University of
California, Davis, School of Medicine; and Tim Surgenor, Partner at Red Sky Partners,
LLC.
Management and speaker presentations will begin at 9:00 a.m. Eastern Time on Tuesday, October 10, 2017 at the offices of
Dechert, LLP in New York City.
A live webcast of the presentation and slide deck will be
available via the Company's Investor Relations website at
http://ir.aldeyra.com. Following the live webcast, an
archived version will be available on the website until
October 10, 2018.
About Aldeyra Therapeutics
Aldeyra
Therapeutics, Inc. is a biotechnology company devoted to
improving lives by inventing, developing and commercializing
products that treat diseases thought to be related to endogenous
aldehydes, a naturally occurring class of pro-inflammatory and
toxic molecules. Aldeyra's lead product candidate, ADX-102,
is an aldehyde trap in development as topical eye drops for the
treatment of ocular inflammation. ADX-102 has now been tested in
over 250 patients in Phase 2 clinical trials in dry eye disease,
allergic conjunctivitis, and noninfectious anterior uveitis. A
dermatologic form of ADX-102 is in late-stage clinical development
for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an
inborn error of aldehyde metabolism. ADX-102 has not been approved
for sale in the U.S. or elsewhere.
Safe Harbor Statement
This release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements regarding Aldeyra's plans and expectations for the
development of ADX-102 and the timing thereof; the potential of
ADX-102 as an agent for the treatment of dry eye disease; the
ability of ADX-102 to provide important patient benefits and a
differentiated mechanism of action relative to existing therapies;
and estimates of the market size for Dry Eye Disease. Aldeyra
intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in
Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. In some cases, you can
identify forward-looking statements by terms such as "may,"
"might," "will," "objective," "intend," "should," "could," "can,"
"would," "expect," "believe," "anticipate," "project," "target,"
"design," "estimate," "predict," "potential," "aim," "plan" or the
negative of these terms, and similar expressions intended to
identify forward-looking statements. Such forward-looking
statements are based upon current expectations that involve risks,
changes in circumstances, assumptions and uncertainties. Aldeyra is
at an early stage of development and may not ever have any products
that generate significant revenue. Important factors that could
cause actual results to differ materially from those reflected in
Aldeyra's forward-looking statements include, among others, the
timing of enrollment, commencement and completion of Aldeyra's
clinical trials, the timing and success of preclinical studies and
clinical trials conducted by Aldeyra and its development partners;
updated or refined data based on Aldeyra's continuing review and
quality control analysis of clinical data, Aldeyra's ability to
design clinical trials with protocols and endpoints acceptable to
applicable regulatory authorities, the ability to obtain and
maintain regulatory approval to conduct clinical trials and to
commercialize Aldeyra's product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs of
developing and commercializing Aldeyra's product candidates; the
size and growth of the potential markets for Aldeyra's product
candidates and the ability to serve those markets; Aldeyra's
expectations regarding Aldeyra's expenses and revenue, the
sufficiency of Aldeyra's cash resources and needs for additional
financing; the rate and degree of market acceptance of any of
Aldeyra's product candidates; Aldeyra's expectations regarding
competition; Aldeyra's anticipated growth strategies; Aldeyra's
ability to attract or retain key personnel; Aldeyra's ability to
establish and maintain development partnerships; Aldeyra's
expectations regarding federal, state and foreign regulatory
requirements; regulatory developments in the United
States and foreign countries; Aldeyra's ability to obtain and
maintain intellectual property protection for its product
candidates; the anticipated trends and challenges in Aldeyra's
business and the market in which it operates; and other factors
that are described in the "Risk Factors " and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations " sections of Aldeyra's Annual Report on Form 10-K for
the year ended December 31, 2016 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 2017, which are on
file with the Securities and Exchange Commission(SEC) and
available on the SEC's website at www.sec.gov. All
of Aldeyra's development timelines may be subject to adjustment
depending on recruitment rate, regulatory review, preclinical and
clinical results, and other factors that could delay the initiation
or completion of clinical trials.
In addition to the risks described above and in Aldeyra's other
filings with the SEC, other unknown or unpredictable factors
also could affect Aldeyra's results. No forward-looking statements
can be guaranteed and actual results may differ materially from
such statements. The information in this release is provided only
as of the date of this release, and Aldeyra undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-2017-research-and-development-day-300526232.html
SOURCE Aldeyra Therapeutics, Inc.